The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Mirum Pharmaceuticals Inc shares valued at $181,980 were purchased by SAIRA RAMASASTRY on Jan 15 ’26. At $90.99 per share, SAIRA RAMASASTRY acquired 2,000 shares.
Also, Ramasastry Saira sold 5,000 shares, netting a total of over 400,000 in proceeds. Following the sale of shares at $80.00 each, the insider now holds 0 shares.
Before that, GREY MICHAEL G had sold 50,000 shares from its account. In a trade valued at $3,900,000, the Director traded Mirum Pharmaceuticals Inc shares for $78.00 each. Upon closing the transaction, the insider’s holdings decreased to 50,000 shares, worth approximately $0.0.
As published in their initiating research note from TD Cowen on September 24, 2025, Mirum Pharmaceuticals Inc [MIRM] has been a Buy and the price target has been revised to $95. Earlier on April 17, 2024, Stifel initiated its rating. Their recommendation was “a Buy” for MIRM stock.
Analyzing MIRM Stock Performance
On last trading session, Mirum Pharmaceuticals Inc [NASDAQ: MIRM] rose 1.84% to $92.32. The stock’s lowest price that day was $85.98, but it reached a high of $92.54 in the same session. During the last five days, there has been a surge of approximately 13.14%. Over the course of the year, Mirum Pharmaceuticals Inc shares have jumped approximately 113.11%.
Support And Resistance Levels for Mirum Pharmaceuticals Inc (MIRM)
RSI (Relative Strength Index) is 76.54 on the 14-day chart, showing overbought technical sentiment.
Is Mirum Pharmaceuticals Inc subject to short interest?
Stocks of Mirum Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.9 million shares to 8.36 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.46 million shares. A jump of 10.74% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.24.
Which companies own the most shares of Mirum Pharmaceuticals Inc (MIRM)?
In terms of Mirum Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 97.5 in the next 12 months, up nearly 7.56% from the previous closing price of $90.65. Analysts anticipate Mirum Pharmaceuticals Inc stock to reach 140 by 2026, with the lowest price target being 89. In spite of this, 9 analysts ranked Mirum Pharmaceuticals Inc stock as Buy at the end of 2026. On December 18, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $58.
